Home/Pipeline/Heparin-based candidate for Alzheimer's

Heparin-based candidate for Alzheimer's

Alzheimer's Disease

Pre-clinicalActive

Key Facts

Indication

Alzheimer's Disease

Phase

Pre-clinical

Status

Active

Company

Intellihep

About Intellihep

IntelliHep is a private, pre-clinical stage biotech exploiting a proprietary platform to engineer novel heparin-based compounds. Its core focus is on in-house development of lead candidates for Alzheimer's disease and cancer, with broader potential applications in inflammation, angiogenesis, and regenerative medicine. Founded in 2019 and based in London, the company is currently pre-revenue and built on a team with deep expertise in heparin glycobiology and chemistry.

View full company profile

Therapeutic Areas

Neurodegeneration Oncology Inflammation Regenerative Medicine

Other Alzheimer's Disease Drugs

Drug	Company	Phase	Status
NUZ-001	Neurizon Therapeutics	Preclinical	Active
ALZN002	Alzamend Neuro	Preclinical	Research
P021	Phanes Biotech	Preclinical	Active
PB43D	Phanes Biotech	Preclinical	Active
UB-311	Vaxxinity	Phase 2	Active
Lecanemab	BioArctic	Launched	Active (Commercial)
BAN2401	BioArctic	Preclinical	Active
Undisclosed Programs	johnson-and-johnson-innovative-medicine	Pipeline	Active
MK-6240 (florquinitau)	Lantheus Medical Imaging	Regulatory Filing	Filed
NAV-4694 (flutafuranol)	Lantheus Medical Imaging	Phase 3	Active
LNTH-2620/PI-2620	Lantheus Medical Imaging	Phase 3	Recruiting
itMSCs	Stemedica Cell Technologies	Clinical Development	Active